respiratori
viral
infect
diseas
renown
major
threat
age
worldwid
particularli
children
year
age
begin
late
sever
epidem
diseas
call
sever
acut
respiratori
syndrom
sar
emerg
china
quickli
spread
countri
area
caus
signific
impact
health
economi
coronaviru
typic
caus
respiratori
enter
diseas
pneumonia
exacerb
asthma
neurolog
symptom
myocard
human
mortal
rate
high
nearli
diagnos
rna
viru
belong
famili
envelop
coronavirus
genom
contain
five
major
open
read
frame
orf
encod
replicas
polyprotein
spike
envelop
e
membran
glycoprotein
nucleocapsid
protein
n
extens
proteolyt
process
nonstructur
structur
polyprotein
vital
step
provid
function
protein
viral
propag
process
mediat
primarili
nonstructur
protein
main
proteas
mpro
dimer
also
known
proteas
analog
monomer
proteas
form
picornaviru
contrast
common
serin
proteas
contain
catalyt
triad
employ
catalyt
dyad
catalyt
site
similar
porcin
transmiss
gastroenter
viru
tgev
human
coronaviru
hcov
use
accord
previou
studi
substrat
specif
proteolyt
site
util
substrat
bulki
hydrophob
residu
mainli
leu
ile
invari
glutamin
residu
small
aliphat
residu
ser
ala
gli
posit
respect
addit
secondari
structur
studi
substrat
reveal
substrat
like
structur
tend
cleav
quickli
determin
crystal
structur
hcov
inhibitor
complex
tgev
also
confirm
remark
degre
conserv
substrat
bind
site
cov
cleav
kda
kda
polyprotein
predict
conserv
site
fig
conserv
sequenc
leu
met
phe
ser
ala
gli
glutamin
residu
invari
posit
fig
liquid
chromatographi
experiment
system
use
analyz
cleav
product
linear
gradient
trifluoroacet
acid
tfa
screen
inhibitor
process
fluorogen
substrat
fluoresc
quench
pair
develop
facilit
enzym
assay
inhibitor
screen
fig
quench
pair
abz
intens
increas
fluoresc
detect
upon
peptid
cleavag
proteas
due
effect
fluoresc
reson
energi
transfer
fret
accompani
fluoresc
plate
reader
fluorogen
substrat
appli
inhibitor
screen
addit
fluorogen
peptid
contain
consensu
cleavag
sequenc
rhodamin
also
serv
substrat
enzym
activ
assay
high
sensit
low
pm
rang
proteas
contain
three
domain
ii
iii
activ
site
locat
domain
ii
crystal
structur
tgev
hcov
reveal
common
featur
cov
two
domain
ii
one
dimer
domain
domain
iii
absent
picornaviru
chymotrypsin
addit
delet
first
four
amino
acid
n
terminu
significantli
increas
dimer
dissoci
constant
k
accordingli
decreas
proteas
activ
analyt
ultracentrifug
auc
analysi
sequenti
delet
first
residu
n
terminu
caus
increas
dimer
k
respect
indic
role
dimer
besid
n
terminu
cluster
conserv
serin
residu
locat
adjac
activ
site
away
dimer
interfac
proteas
initi
cooper
interact
modul
dimer
mutat
ala
make
contact
opposit
subunit
total
abolish
dimer
enzym
activ
howev
measur
k
valu
dimer
vari
recombin
protein
ninta
purif
might
interfer
dimer
format
crystal
structur
residu
buri
dimer
interfac
numer
contact
domain
ii
close
activ
site
protom
fig
first
crystal
structur
complex
hexapeptidyl
chloromethylketon
inhibitor
reveal
structur
featur
proteas
proteas
form
dimer
two
protom
orient
almost
right
angl
catalyt
dyad
locat
activ
site
cleft
domain
ii
adopt
antiparallel
structur
domain
iii
mediat
tight
dimer
contain
five
arrang
larg
antiparallel
globular
cluster
anoth
structur
proteas
six
amino
acid
neighbor
protom
bound
activ
site
form
reveal
detail
interact
proteas
amino
acid
qftvg
structur
two
protom
b
form
dimer
n
terminu
protom
locat
close
activ
site
protom
b
howev
activ
site
protom
b
extra
electron
densiti
origin
six
amino
acid
protom
nearbi
protom
crystal
pack
found
side
chain
gln
last
residu
protom
away
side
chain
ser
first
residu
protom
suggest
posit
shift
autocatalyt
cleavag
prematur
proteas
structur
provid
necessari
inform
ration
design
inhibitor
detail
interact
activ
site
follow
site
side
chain
form
hydrogen
bond
imidazol
ring
carboxyl
oxygen
atom
side
chain
form
backbon
nh
atom
therefor
atom
suitabl
posit
attack
peptid
bond
site
form
atom
well
side
chain
atom
hold
bulki
side
chain
val
leu
phe
posit
n
atom
main
chain
interact
atom
side
chain
interact
hydrophob
interact
side
chain
orient
toward
bulk
solvent
hydrophil
residu
also
exist
posit
atom
accept
atom
n
atom
val
donat
atom
anoth
nh
donat
side
chain
interact
via
hydrophob
interact
subsit
compos
atom
contact
proteas
site
almost
posit
outer
area
protein
howev
atom
still
interact
backbon
n
atom
sever
inhibitor
identifi
differ
laboratori
use
screen
describ
previous
wu
et
al
identifi
activ
compound
assay
block
replic
includ
two
exist
drug
reserpin
aescin
subsequ
target
verif
compound
name
develop
analogu
hiv
proteas
inhibit
constant
k
nm
nm
hiv
proteas
felin
immunodefici
viru
proteas
respect
abl
inhibit
k
measur
fret
assay
fig
lopinavir
one
two
compon
drug
abbott
shown
weakli
inhibit
proteas
k
consist
observ
better
clinic
outcom
treat
sar
patient
drug
hong
kong
hospit
blanchard
et
al
screen
small
molecul
find
five
novel
inhibitor
fig
valu
measur
use
fret
assay
kao
et
al
screen
structur
divers
small
molecul
found
compound
target
one
compound
fig
acid
display
inhibitori
activ
k
valu
cleavag
assay
valu
half
maxim
effect
concentr
vero
plaqu
reduct
assay
without
appar
toxic
half
maxim
cytostat
concentr
compound
fig
imidazolidin
exhibit
k
valu
valu
valu
librari
commerci
avail
drug
biolog
activ
substanc
screen
hsu
et
al
use
assay
find
three
inhibitor
name
phenylmercur
acet
thimeros
hexachlorophen
fig
inhibit
sar
proteas
activ
accord
fret
assay
k
valu
phenylmercur
acet
thimeros
hexachlorophen
determin
respect
phenylmercur
acet
thimeros
contain
mercuri
use
pharmaceut
excipi
wide
use
antimicrobi
preserv
parenter
topic
pharmaceut
formul
shown
compound
compound
also
identifi
proteas
inhibitor
hexachlorophen
deriv
explor
inhibitor
similar
inhibitori
activ
use
fret
assay
liu
et
al
chen
et
al
screen
natur
product
librari
consist
compound
obtain
two
compound
tannic
acid
half
maxim
inhibitori
concentr
inhibitor
assay
two
larg
compound
structur
shown
belong
group
natur
polyphenol
tea
also
natur
product
librari
acid
ethyl
ester
fig
valu
deriv
marin
spong
axinella
corrug
screen
perform
use
sensit
intern
quench
fluorogen
substrat
also
base
fret
cal
fluor
red
black
hole
pair
assay
effect
inhibitor
replic
vero
cell
concentr
dragovich
et
al
synthes
seri
compound
target
rhinoviru
proteas
possibl
treatment
human
common
cold
best
inhibitor
ketomethyl
isoster
ester
rhinoviru
proteas
inhibitor
valu
inhibit
rhinoviru
proteas
moieti
mimic
glutamin
residu
ester
act
michael
acceptor
inhibit
rhinoviru
form
coval
bond
activ
site
cy
residu
improv
cell
membran
permeabl
phenylalanin
residu
replac
methylen
isoster
bear
substitu
although
potent
inhibitor
rhinoviru
approv
clinic
use
due
lack
obviou
advantag
treat
patient
common
cold
et
al
agouron
pharmaceut
inc
appli
us
patent
entitl
inhibitor
sar
like
proteas
applic
compound
michael
acceptor
inhibit
two
formula
propos
potenti
sar
proteas
inhibitor
fig
without
give
activ
data
kania
et
al
pfizer
inc
develop
seri
compound
structur
featur
isobutyl
group
inhibit
describ
world
patent
entitl
anticoronavir
compound
composit
pharmaceut
use
materi
synthesi
compound
shown
provid
protect
vero
cell
hcov
infect
viabil
assay
although
structur
featur
compound
inact
show
inhibitori
activ
best
compound
seri
display
valu
fig
inhibit
replic
target
without
toxic
gener
formula
given
fig
rao
et
al
appli
patent
cover
seri
analogu
common
structur
compound
fig
inhibitor
sar
use
continu
fluorometr
assay
fluorogen
substrat
dnp
effect
compound
fig
seri
inhibit
k
k
inact
rate
enzym
inactiv
also
proteas
hcov
tgev
felin
infecti
periton
viru
mous
hepat
viru
infecti
bronchiti
viru
compound
exhibit
valu
mous
hepat
viru
murin
delay
brain
tumour
cell
assay
also
low
toxic
compound
display
inhibit
cell
growth
yang
et
al
discov
potent
inhibitor
analogu
cyclic
posit
k
compound
fig
base
hplc
assay
inhibitor
exhibit
potent
activ
suppress
replic
log
viral
titer
reduct
concentr
cytotox
hcov
log
viral
titer
reduct
concentr
tight
bind
coval
bond
hydrogen
bond
unpreced
hydrophob
interact
evidenc
crystal
structur
correspond
complex
shie
et
al
found
replac
moieti
phenylalanin
side
chain
result
potent
inhibitor
shown
fig
best
inhibitor
seri
k
valu
measur
fret
assay
compound
also
show
potent
activ
replic
block
synthesi
viral
spike
protein
without
appar
toxic
assay
comput
model
phenylalanin
side
chain
posit
may
shift
one
posit
occupi
site
michael
acceptor
coval
bound
accord
crystal
structur
hydrophob
pocket
hold
hydrophob
residu
side
chain
expos
solvent
seri
peptid
anilid
anilin
deriv
next
shown
inhibit
also
viral
replic
compound
shown
fig
potent
inhibitor
k
valu
use
fret
assay
delet
chloro
nitro
dimethylamino
substitu
compound
significantli
weaken
bind
affin
also
replac
dimethylamino
group
nitro
group
caus
reduct
inhibitor
potenc
accord
molecular
dock
nitro
group
compound
predict
hydrogen
bond
nh
chlorin
atom
within
atom
atom
therefor
provid
possibl
key
interact
catalyt
dyad
recogn
glutamin
residu
site
jain
et
al
synthes
evalu
seri
analogu
phthalhydrazido
group
posit
revers
proteas
inhibitor
attach
tripeptid
warhead
result
significantli
better
inhibitor
n
analogu
much
less
potent
inhibitor
larger
cyclic
glutamin
analogu
best
inhibitor
fig
show
valu
measur
use
fret
assay
model
structur
inhibitor
bound
extend
conform
form
partial
hydrogen
bond
side
chain
model
studi
indic
activ
site
enzym
enough
room
accommod
bulki
phthalhydrazido
group
rearrang
protein
particular
residu
requir
accommod
extra
bulki
group
residu
zhang
et
al
design
synthes
seri
dipeptidyl
glutaminyl
fluoromethyl
keton
fig
coval
inhibit
react
activ
site
cy
residu
inhibitor
synthes
use
n
residu
warhead
combin
differ
amino
acid
via
reaction
dipeptid
hydrophob
residu
leu
val
phe
posit
show
better
effect
infect
vero
cell
consist
proteas
substrat
prefer
best
inhibitor
shown
fig
valu
test
vero
cell
toxic
valu
inhibitor
howev
compound
gli
ala
amino
acid
inhibit
viral
replic
similar
fluoromethyl
keton
aziridin
epoxid
also
react
nucleophil
amino
acid
within
activ
site
proteas
screen
use
assay
identifi
name
fig
modest
inhibitor
enzym
activ
inhibit
compound
activ
may
enhanc
link
electrophil
build
block
appropri
amino
acid
eg
gln
substrat
analog
peptid
peptidomimet
epoxid
fig
also
found
inhibit
coval
k
valu
k
inact
x
accord
complex
crystal
structur
epoxid
ring
inhibitor
open
upon
cy
attack
leav
hydroxyl
group
atom
form
hydrogen
bond
atom
proteas
carbonyl
atom
inhibitor
configur
atom
invert
r
r
shella
et
al
appli
patent
entitl
inhibitor
sever
acut
respiratori
syndrom
sar
discov
pharmaceut
compound
includ
three
compon
fig
inhibit
sar
rhinoviru
mammal
administ
effect
amount
rhinoviru
inhibitor
howev
assay
data
avail
cai
et
al
found
compound
gener
structur
compound
fig
inhibit
felin
infecti
periton
viru
describ
patent
entitl
proteas
inhibitor
coronavirus
use
thereof
inventor
perform
assay
use
infect
cell
murin
delay
brain
tumor
cell
infect
mous
hepat
viru
strain
vero
cell
infect
found
compound
could
inhibit
virus
protect
cell
infect
suggest
compound
may
administ
mammal
human
oral
dose
mg
equival
amount
pharmaceut
accept
salt
thereof
per
day
bodi
weight
mammal
treat
disord
prefer
mg
oral
administ
treat
prevent
disord
intramuscular
inject
dose
gener
oral
dose
certain
isatin
deriv
known
potent
inhibitor
rhinoviru
isatin
core
structur
offer
sever
advantag
includ
eas
synthesi
chemic
modif
deriv
test
inhibitor
sar
seri
synthet
isatin
deriv
show
valu
rang
fret
assay
confirm
assay
best
inhibitor
found
list
fig
iodin
brom
atom
isatin
scaffold
conclud
benzothiophenemethyl
side
chain
provid
inhibitori
effect
benzyl
heterocycl
substitut
methyl
alkyl
group
recent
zhou
et
al
report
seri
isatin
deriv
inhibit
activ
measur
continu
colorimetr
assay
use
colorimetr
substrat
posit
isatin
found
favor
carboxamid
group
posit
favor
larg
hydrophob
substitu
inhibit
proteas
lowest
valu
observ
among
inhibitor
shown
screen
compound
compound
phenylmercur
acet
thimeros
identifi
potent
inhibitor
contain
mercuri
fig
suggest
use
metal
ion
chelat
cy
proteas
metal
ion
high
affin
sulfur
atom
cy
residu
compound
may
pose
therapeut
hazard
patient
oral
taken
seri
compound
metal
ion
evalu
inhibit
potent
inhibitor
found
zinc
competit
inhibitor
k
valu
fig
inhibitori
activ
k
previous
found
tetrahedr
coordin
three
cy
sulfur
one
nitrogen
proteas
common
cold
viru
respons
protein
synthesi
compound
zinc
acet
ad
supplement
drug
treatment
wilson
diseas
indic
safeti
ion
human
use
zinc
salt
zincum
gluconicum
zenullos
may
effect
treat
common
cold
diseas
caus
rhinovirus
without
knowledg
molecular
target
moreov
zinc
ion
inhibit
replic
rhinovirus
thu
potenti
use
compound
therapeut
treatment
sar
diseas
need
explor
bacha
et
al
propos
attract
subsit
design
potent
inhibitor
fig
cluster
ser
residu
close
catalyt
residu
fact
ser
cluster
conserv
known
cov
proteas
may
repres
common
target
cov
proteas
inhibitor
base
known
reactiv
boron
acid
compound
hydroxyl
group
ser
residu
inhibitori
potenc
bifunct
boron
acid
compound
evalu
chemic
scaffold
contain
two
phenyl
boron
group
attach
central
aromat
ring
ester
linkag
test
compound
k
valu
base
fret
assay
differ
variat
compound
prepar
includ
sever
isom
replac
central
aromat
ring
shorter
ester
linkag
differ
function
phenyl
boron
ring
highest
improv
affin
observ
ester
linkag
aromat
ring
replac
amid
group
therebi
result
nanomolar
inhibit
constant
inhibitor
display
mix
competit
pattern
bind
free
enzym
enzym
substrat
complex
may
due
larg
substrat
use
kinet
measur
compound
inhibit
enzym
revers
manner
freir
et
al
provid
seri
organ
compound
compound
repres
exampl
fig
composit
thereof
method
use
compound
composit
inhibit
cov
proteas
treat
infect
invent
provid
method
inhibit
cov
proteas
treat
infect
caus
cov
detect
cov
particularli
cov
proteas
one
serin
threonin
residu
near
activ
site
proteas
cov
method
compris
contact
test
sampl
obtain
patient
compound
tether
appropri
surfac
proteas
come
contact
bound
tether
compound
detect
ii
label
fluoresc
radioact
marker
allow
identif
cov
proteas
bound
compound
iii
mean
use
detect
presenc
cov
proteas
shown
fluoromethyl
keton
aziridinyl
peptid
inhibitor
scrutin
compound
contain
electrophil
build
block
aziridin
epoxid
michael
system
known
react
nucleophil
amino
acid
within
activ
site
proteas
deriv
etacryn
acid
diuret
drug
contain
activ
doubl
bond
also
shown
inhibitor
comprehens
screen
assay
perform
promis
inhibitor
etacryn
acid
fig
inhibit
proteas
k
measur
fret
assay
class
stabl
benzotriazol
ester
report
inactiv
prepar
librari
compound
variou
carboxyl
acid
coupl
amin
presenc
hexafluorophosph
hbtu
intermedi
acid
hbtu
found
inhibit
proteas
compound
purifi
character
potent
inhibitor
figur
show
k
valu
nm
coval
inhibitor
specif
acyl
residu
k
inact
balzarini
et
al
patent
novel
glycopeptid
antibiot
deriv
compound
fig
process
prepar
use
medicin
use
treat
prevent
viral
infect
use
manufactur
medicin
treat
prevent
viral
infect
invent
cover
use
glycopeptid
antibiot
includ
vancomycin
teicoplanin
ristomycin
aglycon
semisynthet
deriv
treat
prevent
viral
infect
especi
infect
virus
belong
retrovirida
herpesvirida
flavivirida
coronavirida
hiv
hepat
c
viru
bovin
viral
diarrhoea
viru
felin
cov
herp
simplex
viru
varicella
zoster
viru
cytomegaloviru
lu
et
al
perform
virtual
screen
chemic
databas
contain
compound
follow
test
potenti
inhibitor
identifi
hit
one
hit
phenylsulfonyl
pyridin
valu
fig
measur
use
fret
assay
core
structur
diphenyl
sulfon
compound
use
search
analogu
analogu
measur
inhibit
constant
sar
proteas
wu
et
al
file
patent
relat
method
modul
activ
analogu
thereof
contact
protein
effect
amount
seri
diphenyl
sulfon
analogu
invent
base
discoveri
group
dicycl
compound
effect
inhibit
activ
hepat
c
viru
proteas
structur
analogu
anoth
compound
identifi
virtual
screen
lu
et
al
methyl
thio
chlorid
valu
fig
core
structur
shown
bold
use
search
structur
analogu
nine
compound
moder
structur
similar
found
inhibit
use
virtual
screen
studi
tsai
et
al
discov
group
inhibitor
call
pyrimidinylthio
acetamid
file
patent
applic
potent
one
analogu
valu
fret
assay
shown
fig
core
structur
highlight
bold
chen
et
al
perform
virtual
screen
exist
medic
databas
cmc
comprehens
medicin
chemistri
mdl
inform
system
inc
inhibitor
use
structur
cinanserin
fig
identifi
inhibit
proteas
two
patent
file
valu
cinanserin
inhibit
hcov
proteas
found
respect
use
fret
assay
cinanserin
also
found
block
replic
tissu
cultur
treatment
cell
cinanserin
reduc
rna
concentr
log
unit
valu
reduct
titr
infecti
particl
exactli
correspond
reduct
viru
rna
concentr
toxic
compound
detect
concentr
rang
test
lai
et
al
use
comput
model
simul
structur
obtain
calamidazolium
fig
potenti
inhibitor
hplc
assay
use
verifi
compound
inde
inhibit
enzym
shen
et
al
use
structur
pdb
id
tgev
mpro
templat
simul
structur
model
identifi
activ
site
molecular
dock
screen
compound
commerci
data
bank
inhibitor
seri
analogu
core
structur
compound
fig
found
inhibit
recombin
sar
prevent
viru
infect
cell
addit
serv
promis
target
chemotherapi
possess
potenti
endopeptidas
analog
picornavirus
proteas
substrat
specif
cleav
amid
bond
small
amino
acid
ser
ala
gli
accord
structur
small
residu
near
like
limit
substrat
specif
sinc
recombin
undergo
modif
might
toler
larg
amino
acid
posit
fact
mutat
expand
site
thu
abl
cleav
peptid
larger
amino
acid
met
start
amino
acid
nativ
protein
fig
inde
compar
k
cat
k
mutant
display
k
cat
k
higher
k
catk
substrat
moreov
vector
contain
nucleotid
encod
recognit
site
tag
met
target
protein
construct
express
prokaryot
eukaryot
host
vector
psti
ctgcag
chosen
clone
site
sinc
sequenc
overlap
nucleotid
sequenc
gcggtgctgcag
encod
proteas
recognit
site
fig
ident
clone
site
vector
use
allow
dna
fragment
target
gene
gener
pcr
ligat
vector
simultan
parallel
clone
method
engin
vector
mutant
assembl
kit
maxim
product
solubl
function
protein
authent
sequenc
see
patent
entitl
protein
express
system
involv
mutat
sever
respiratori
coronaviru
proteas
liang
et
al
sinc
viral
proteas
inhibitor
remark
effect
block
viral
replic
cytopath
effect
inhibit
proteolysi
convinc
strategi
review
articl
effect
inhibitor
summar
methodolog
detect
proteas
activ
inhibitor
screen
discuss
peptidomimet
inhibitor
design
base
substrat
specif
phe
replac
gln
moieti
coval
inhibitor
electrophil
structur
featur
michael
acceptor
ester
fluoromethyl
keton
aziridin
epoxid
etacryn
acid
built
react
cy
residu
compound
also
target
residu
compound
suggest
bind
activ
site
sar
proteas
base
comput
model
potenti
inhibitor
inhibitor
may
also
use
inhibit
viral
proteas
due
degre
structur
similar
activ
site
fact
inhibitor
deriv
previous
identifi
rhinoviru
inhibitor
call
rupintrivir
rupintrivir
potent
inhibitor
base
vitro
vivo
studi
analogu
modifi
base
structur
differ
repres
promis
lead
agent
sever
class
inhibitor
also
inhibit
picornavir
structur
studi
reveal
monom
wherea
dimer
protein
extra
third
domain
dimer
format
although
activ
site
superimpos
well
moreov
open
shallow
site
well
smaller
site
account
differ
inhibitori
specif
conclud
structur
comparison
inhibitor
activ
site
moreov
inhibitor
could
possibl
serv
new
drug
lead
viral
diseas
caus
rhinoviru
hcov
enteroviru
transmiss
gastroenter
viru
felin
infecti
periton
viru
mous
hepat
viru
infecti
bronchiti
viru
particularli
recent
emerg
coronaviru
human
betacoronaviru
also
call
middl
east
respiratori
syndrom
coronaviru
structur
similar
proteas
inhibit
fig
rupintrivir
analogu
inhibit
moreov
inhibitor
also
inhibit
activ
therefor
inform
discuss
present
review
help
ultim
develop
drug
infecti
cov
picornavirus
continu
pursu
mutant
sar
recogn
cleav
fusion
protein
effici
result
serv
novel
endopeptidas
tag
cleavag
fusion
protein
express
e
coli
yeast
pichia
contain
avlq
sequenc
immedi
met
residu
moreov
mutant
proteas
also
show
similar
cleavag
effici
commonli
use
fxa
cleav
tag
condit
vector
differ
express
system
includ
insect
cell
mammalian
cell
system
could
also
construct
contain
proteas
recognit
site
common
restrict
site
use
parallel
clone
pcr
product
target
gene
vector
engin
vector
mutant
proteas
assembl
kit
parallel
express
target
gene
multipl
host
simultan
screen
optim
condit
produc
solubl
function
protein
maxim
yield
fusion
protein
purifi
affin
column
tag
eg
ninta
tag
remov
yield
recombin
protein
authent
sequenc
author
declar
conflict
interest
symbol
usedkd
dimer
dissoci
constantki
inhibit
constantkinact
rate
enzym
inactiv
proteaseaucanalyt
maxim
cytostat
concentrationcmccomprehens
medicin
maxim
effect
concentrationfretfluoresc
reson
energi
hexafluorophosphatehcovhuman
maxim
inhibitori
concentrationmmembran
glycoproteinsmpromain
proteasennucleocapsid
proteinnspnonstructur
proteinorfopen
read
liquid
chromatographysspikesarssever
acut
respiratori
acidtgevtransmiss
gastroenter
viru
publish
receiv
permiss
copyright
owner
includ
object
version
product
pleas
refer
either
publish
onlin
version
product
print
product
one
exist
kuo
receiv
doctor
nation
taiwan
univers
supervis
dr
liang
dissert
develop
fluorogen
substrat
activ
detect
sar
proteas
inhibitor
screen
work
postdoctor
fellow
chang
group
cornel
univers
depart
popul
medicin
diagnost
scienc
current
assist
professor
depart
veterinari
medicin
nation
chung
hsing
univers
taiwan
publish
receiv
permiss
copyright
owner
includ
object
version
product
pleas
refer
either
publish
onlin
version
product
print
product
one
exist
liang
current
research
fellow
institut
biolog
chemistri
academia
sinica
joint
professor
institut
biochem
scienc
nation
taiwan
univers
taiwan
research
theme
enzymolog
drug
discoveri
enzym
engin
work
subject
enzymolog
prenyltransferas
mechanist
approach
discov
drug
enzym
engin
biofuel
product
